LEO Pharma mounts another challenge to the eczema giants, betting $40M cash on a drug from China
LEO Pharma knows it’s in for a brawl with powerful players in atopic dermatitis. With some positive Phase III data in and regulatory filings on the way, the Danish drugmaker is shelling out $40 million upfront on a new drug candidate that goes at both eczema and asthma from a different angle.
The asset, FB825, comes out of a collaboration between Oneness Biotech in Taiwan and Microbio Shanghai in China. It hits the CεmX domain of the membrane bound IgE (mIgE), causing a depletion of mIgE positive B-cells and thereby lowering inflammation.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.